Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Author information

1
Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
2
1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
3
Department of Medicine, Duke University, Durham, North Carolina, USA.
4
1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.
5
Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.
6
Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
7
Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.
8
1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
9
Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
10
Department of Genetics, Stanford University, Palo Alto, California, USA.
11
Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
12
1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01894230.

PMID:
24918167
PMCID:
PMC4169720
DOI:
10.1038/clpt.2014.125
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Secondary source ID, Grant support

Publication types

MeSH terms

Substances

Secondary source ID

Grant support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center